CRMD · Healthcare · $604M
$7.70-2.90%
What's this stock's score right now?
See its score for free — revenue and money flow, graded on one standard.
Quarterly Financials
9/'26
6/'26 vs prev quarter
Among 327 Biotechnology peers
Quarterly Revenue Growth
“이번 분기 매출은 1억190만 달러로 직전 분기 1억2,700만 달러에서 줄었지만, 이는 DefenCath 수요 붕괴보다 Melinta 인수 효”
In the company's words · 2026 2분기 earnings call